Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update

Table 3

MSC-EV treatment trials in COVID-19 registered on Clinical Trials. The treatment of COVID-19 disease, including trial numbers, source of EVs, routes of administration, and primary endpoints.

Trial ID no.	Status	Responsible country	Source of extracellular vesicles	Administration	Primary endpoints
NCT04276987	Completed	China	Exosome derived from allogenic adipose mesenchymal stem cells	Inhalation	Adverse reaction
NCT04491240	Completed has results	Russian Federation	MSC exosomes	Inhalation	Adverse events
NCT04493242	Not recruiting	United States	Bone marrow-derived extracellular vesicles	IV	All-cause mortality
NCT04602442	Enrolling by invitation	Russian Federation	Mesenchymal stem cell exosomes	Inhalation	Adverse events during trial
NCT04657458	Available	United States	Bone marrow-derived extracellular vesicles	IV	Not recorded
NCT04798716	Not recruiting	United States	MSC exosomes	IV	Adverse events